Toll Free: 1-888-928-9744

Intas Pharmaceuticals Ltd. - Product Pipeline Review - 2014

Published: Oct, 2014 | Pages: 30 | Publisher: Global Markets Direct
Industry: Pharmaceutical | Report Format: Electronic (PDF)

Intas Pharmaceuticals Ltd. - Product Pipeline Review - 2014

Summary

Global Markets Direct's, 'Intas Pharmaceuticals Ltd. - Product Pipeline Review - 2014', provides an overview of the Intas Pharmaceuticals Ltd.'s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Intas Pharmaceuticals Ltd.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides brief overview of Intas Pharmaceuticals Ltd. including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of Intas Pharmaceuticals Ltd.'s human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones 
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement 
- Latest news and deals relating to the Intas Pharmaceuticals Ltd.'s pipeline products

Reasons to buy

- Evaluate Intas Pharmaceuticals Ltd.'s strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of Intas Pharmaceuticals Ltd. in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the Intas Pharmaceuticals Ltd.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of Intas Pharmaceuticals Ltd. and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of Intas Pharmaceuticals Ltd.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of Intas Pharmaceuticals Ltd. and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues
 Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Intas Pharmaceuticals Ltd. Snapshot 5
Intas Pharmaceuticals Ltd. Overview 5
Key Information 5
Key Facts 5
Intas Pharmaceuticals Ltd. - Research and Development Overview 6
Key Therapeutic Areas 6
Intas Pharmaceuticals Ltd. - Pipeline Review 8
Pipeline Products by Stage of Development 8
Pipeline Products - Monotherapy 9
Pipeline Products - Partnered Products 10
Partnered Products/Combination Treatment Modalities 11
Intas Pharmaceuticals Ltd. - Pipeline Products Glance 12
Intas Pharmaceuticals Ltd. - Late Stage Pipeline Products 12
Phase III Products/Combination Treatment Modalities 12
Intas Pharmaceuticals Ltd. - Clinical Stage Pipeline Products 13
Phase I Products/Combination Treatment Modalities 13
Intas Pharmaceuticals Ltd. - Drug Profiles 14
etanercept biosimilar 14
Product Description 14
Mechanism of Action 14
R&D Progress 14
INASTR-001 15
Product Description 15
Mechanism of Action 15
R&D Progress 15
INSUPR-001 16
Product Description 16
Mechanism of Action 16
R&D Progress 16
Peg-EPO 17
Product Description 17
Mechanism of Action 17
R&D Progress 17
ranibizumab biosimilar 18
Product Description 18
Mechanism of Action 18
R&D Progress 18
ulipristal acetate 19
Product Description 19
Mechanism of Action 19
R&D Progress 19
Drug for Cancer and Neurodegenerative Disease 20
Product Description 20
Mechanism of Action 20
R&D Progress 20
Intas Pharmaceuticals Ltd. - Pipeline Analysis 21
Intas Pharmaceuticals Ltd. - Pipeline Products by Target 21
Intas Pharmaceuticals Ltd. - Pipeline Products by Route of Administration 22
Intas Pharmaceuticals Ltd. - Pipeline Products by Molecule Type 23
Intas Pharmaceuticals Ltd. - Pipeline Products by Mechanism of Action 24
Intas Pharmaceuticals Ltd. - Dormant Projects 25
Intas Pharmaceuticals Ltd. - Company Statement 26
Intas Pharmaceuticals Ltd. - Locations And Subsidiaries 27
Head Office 27
Other Locations & Subsidiaries 27
Intas Pharmaceuticals Ltd. - Key Manufacturing Facilities 28
Appendix 29
Methodology 29
Coverage 29
Secondary Research 29
Primary Research 29
Expert Panel Validation 29
Contact Us 30
Disclaimer 30
List of Tables
Intas Pharmaceuticals Ltd., Key Information 5
Intas Pharmaceuticals Ltd., Key Facts 5
Intas Pharmaceuticals Ltd. - Pipeline by Indication, 2014 7
Intas Pharmaceuticals Ltd. - Pipeline by Stage of Development, 2014 8
Intas Pharmaceuticals Ltd. - Monotherapy Products in Pipeline, 2014 9
Intas Pharmaceuticals Ltd. - Partnered Products in Pipeline, 2014 10
Intas Pharmaceuticals Ltd. - Partnered Products/ Combination Treatment Modalities, 2014 11
Intas Pharmaceuticals Ltd. - Phase III, 2014 12
Intas Pharmaceuticals Ltd. - Phase I, 2014 13
Intas Pharmaceuticals Ltd. - Pipeline by Target, 2014 21
Intas Pharmaceuticals Ltd. - Pipeline by Route of Administration, 2014 22
Intas Pharmaceuticals Ltd. - Pipeline by Molecule Type, 2014 23
Intas Pharmaceuticals Ltd. - Pipeline Products by Mechanism of Action, 2014 24
Intas Pharmaceuticals Ltd. - Dormant Developmental Projects,2014 25
Intas Pharmaceuticals Ltd., Other Locations 27
Intas Pharmaceuticals Ltd., Subsidiaries 27
Intas Pharmaceuticals Ltd., Key Manufacturing Facilities 28 



                                

To request a free sample copy of this report, please complete the form below.

We never share your personal data. Privacy policy
Interested in this report? Get your FREE sample now! Get a Free Sample
Choose License Type
Single User - US $1500
Multi User - US $3000
Hexareeasearch Know

Did you know?

Research Assistance

Phone: 1-415-349-0054

Toll Free: 1-888-928-9744

Email: [email protected]

Why to buy from us

Custom research service

Speak to the report author to design an exclusive study to serve your research needs.

Information security

Your personal and confidential information is safe and secure.

verify